The role of semaphorin 4D as a potential biomarker for antiangiogenic therapy in colorectal cancer
Open Access
- 1 March 2016
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. 9, 1189-1204
Abstract
Background: Semaphorin 4D (Sema4D) belongs to the class IV semaphorins, and accumulating evidence has indicated that its elevated level may be one strategy by which tumors evade current antiangiogenic therapies. The biological roles of Sema4D in colorectal cancer (CRC), however, remain largely undefined. This study was designed to investigate the effects of Sema4D on tumor angiogenesis and growth in CRC, especially in different vascular endothelial growth factor (VEGF) backgrounds. Methods: The expression of Sema4D in human CRC was evaluated by immunohistochemical analysis of tumors and their matching normal control tissues. The expression level of Sema4D and VEGF was investigated in different CRC cell lines. To evaluate the contributions of Sema4D to tumor-induced angiogenesis, two CRC cell lines with opposite VEGF backgrounds were infected with lentiviruses expressing Sema4D or Sema4D short hairpin RNA, followed by in vitro migration and in vivo tumor angiogenic assays. Results: Immunohistochemical analysis of human CRC revealed high levels of Sema4D in a cell surface pattern. In all, 84.85% of CRC samples analyzed exhibited moderate to strong Sema4D expression. The positive ratios of Sema4D staining for well, moderately, and poorly differentiated cancers were 71.43%, 96.67%, and 77.27%, respectively. Sema4D is highly expressed in five different CRC cell lines, while VEGF expression level varies among these cell lines. HCT-116 showed the lowest VEGF level, while Caco-2 showed the maximum VEGF level. In vitro migration results show that regardless of cell type and VEGF background, Sema4D showed an enhanced in vitro proangiogenic effect to induce the migration of human umbilical vein endothelial cells. Finally, in vivo tumor angiogenic assays demonstrated that Sema4D alone can elicit a significant angiogenic response to promote tumor growth independently of VEGF. Conclusion: Targeting Sema4D might serve as a parallel option for antiangiogenic therapy for CRC, particularly when traditional anti-VEGF therapies fail or tumors develop resistance to strategies targeting a single angiogenic signaling pathway.Keywords
This publication has 37 references indexed in Scilit:
- Comparison of Gene-Transfer Efficiency in Human Embryonic Stem CellsMolecular Imaging and Biology, 2009
- Prognostic significance of CD100 expression in soft tissue sarcomaCancer, 2007
- Plexin-B1 plays a redundant role during mouse development and in tumour angiogenesisBMC Developmental Biology, 2007
- Lessons from phase III clinical trials on anti-VEGF therapy for cancerNature Clinical Practice Oncology, 2006
- Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumorsCancer Cell, 2005
- Semaphorin 4D/Plexin-B1 Induces Endothelial Cell Migration through the Activation of PYK2, Src, and the Phosphatidylinositol 3-Kinase–Akt PathwayMolecular and Cellular Biology, 2005
- A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesisCytokine & Growth Factor Reviews, 2005
- Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implicationsSeminars in Oncology, 2002
- VEGF-A Induces Angiogenesis, Arteriogenesis, Lymphangiogenesis, and Vascular MalformationsCold Spring Harbor Symposia on Quantitative Biology, 2002
- Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector.Proceedings of the National Academy of Sciences of the United States of America, 1996